Company logo

CYTK - Cytokinetics, Incorporated

NASDAQ -> Healthcare -> Biotechnology
South San Francisco, United States
Type: Equity

CYTK price evolution
CYTK
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Current assets
Cash $113.02 $99.69 $68.64 $101.62
Short term investments $501.8 $439.55 $497.08 $562.35
Net receivables $1.28 $2.5 $0.98 $1.01
Inventory
Total current assets $628.05 $561.42 $586.58 $680.63
Long term investments $40.53 $15.47 $26.87 $40.41
Property, plant & equipment $147.74 $155.54 $158.11 $160.66
Goodwill & intangible assets
Total noncurrent assets $196.26 $179.2 $193.32 $209.19
Total investments $542.33 $455.01 $523.95 $602.75
Total assets $824.32 $740.61 $779.9 $889.82
Current liabilities
Accounts payable $21.51 $13.8 $12.56 $17.36
Deferred revenue
Short long term debt $27.97 $17.24 $15.7 $14.26
Total current liabilities $102.68 $77.72 $65.62 $75.22
Long term debt $727.8 $731.24 $733.61 $735.96
Total noncurrent liabilities $1107.96 $1101.69 $1047.4 $1043.62
Total debt $755.77 $748.47 $749.31 $750.23
Total liabilities $1210.64 $1179.41 $1113.01 $1118.84
Shareholders' equity
Retained earnings -$2112.24 -$1975.34 -$1845.92 -$1717.28
Other shareholder equity -$0.01 -$0.87 -$1.46 -$1.65
Total shareholder equity -$386.32 -$438.8 -$333.12 -$229.02
(in millions $) 31 Dec 2023 31 Jan 2023 31 Dec 2021 31 Dec 2020
Current assets
Cash $113.02 $65.58 $112.67 $82.98
Short term investments $501.8 $717 $358.97 $381.07
Net receivables $1.28 $0.15 $51.82 $4.42
Inventory
Total current assets $628.05 $795.19 $535.67 $474.22
Long term investments $40.53 $46.71 $152.05 $36.95
Property, plant & equipment $147.74 $163.19 $146.41 $22.63
Goodwill & intangible assets
Total noncurrent assets $196.26 $219.59 $305.65 $59.58
Total investments $542.33 $763.7 $511.02 $418.03
Total assets $824.32 $1014.77 $841.32 $533.8
Current liabilities
Accounts payable $21.51 $25.61 $21.09 $8.05
Deferred revenue $87 $87
Short long term debt $27.97 $12.83 $14.86 $2.79
Total current liabilities $102.68 $84.62 $71.86 $31.2
Long term debt $727.8 $610.62 $255.07 $136.15
Total noncurrent liabilities $1107.96 $1038.06 $525.6 $389.22
Total debt $755.77 $749.34 $269.93 $138.94
Total liabilities $1210.64 $1122.67 $597.46 $420.42
Shareholders' equity
Retained earnings -$2112.24 -$1585.99 -$1207.62 -$992.31
Other shareholder equity -$0.01 -$3.59 -$0.87 $0.15
Total shareholder equity -$386.32 -$107.9 $243.86 $113.38
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Revenue
Total revenue $1.67 $0.38 $0.87 $4.61
Cost of revenue
Gross Profit $1.67 $0.38 $0.87 $4.61
Operating activities
Research & development $84.98 $82.53 $83.19 $79.42
Selling, general & administrative $44.11 $40.11 $39.72 $49.66
Total operating expenses $129.09 $122.64 $122.92 $129.09
Operating income -$127.42 -$122.27 -$122.05 -$124.47
Income from continuing operations
EBIT -$129.73 -$122.29 -$121.59 -$124.33
Income tax expense
Interest expense $7.16 $7.14 $7.04 $6.96
Net income
Net income -$136.9 -$129.42 -$128.64 -$131.29
Income (for common shares) -$136.9 -$129.42 -$128.64 -$131.29
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Revenue
Total revenue $7.53 $94.59 $70.43 $55.83
Cost of revenue
Gross Profit $7.53 $94.59 $70.43 $55.83
Operating activities
Research & development $330.12 $240.81 $159.94 $96.95
Selling, general & administrative $173.61 $177.98 $96.8 $52.82
Total operating expenses $503.74 $418.79 $256.74 $149.77
Operating income -$496.2 -$324.2 -$186.31 -$93.94
Income from continuing operations
EBIT -$497.94 -$369.54 -$198.87 -$111.33
Income tax expense
Interest expense $28.31 $19.41 $16.44 $15.96
Net income
Net income -$526.24 -$388.95 -$215.31 -$127.29
Income (for common shares) -$526.24 -$388.95 -$215.31 -$127.29
(in millions $) 31 Dec 2023 30 Sep 2023 30 Jun 2023 31 Mar 2023
Net income -$136.9 -$129.42 -$128.64 -$131.29
Operating activities
Depreciation $6.33 $1.85 $1.85 $1.85
Business acquisitions & disposals
Stock-based compensation $19.49 $18.72 $18.67 $15.19
Total cash flows from operations -$74.04 -$96.2 -$121.81 -$122.29
Investing activities
Capital expenditures -$0.08 -$0.22 -$0.72 -$0.4
Investments -$81.33 $73.26 $82.84 $165.9
Total cash flows from investing -$81.41 $73.04 $82.13 $165.5
Financing activities
Dividends paid
Sale and purchase of stock $169.02 $4.44 $5.69 $3.55
Net borrowings -$0.22 -$0.22 -$0.21 -$0.21
Total cash flows from financing $168.8 $54.22 $5.47 -$7.18
Effect of exchange rate -$0.02
Change in cash and equivalents $13.33 $31.05 -$34.2 $36.03
(in millions $) 31 Dec 2023 31 Dec 2022 31 Dec 2021 31 Dec 2020
Net income -$526.24 -$388.95 -$215.31 -$127.29
Operating activities
Depreciation $11.89 $5.81 $2.28 $1.83
Business acquisitions & disposals
Stock-based compensation $72.06 $47.85 $26.83 $17.62
Total cash flows from operations -$414.33 -$299.52 -$142.52 $8.94
Investing activities
Capital expenditures -$1.42 -$11.34 -$48.87 -$11.05
Investments $240.67 -$250.8 -$98.91 -$185.46
Total cash flows from investing $239.25 -$262.13 -$147.78 -$196.51
Financing activities
Dividends paid
Sale and purchase of stock $182.69 $17.54 $319.98 $231.97
Net borrowings -$0.86 $332.25
Total cash flows from financing $221.32 $516.17 $319.98 $234.12
Effect of exchange rate -$0.02
Change in cash and equivalents $46.22 -$45.48 $29.68 $46.55
Fundamentals
Market cap $7.00B
Enterprise value $7.64B
Shares outstanding 98.05M
Revenue $7.53M
EBITDA -$486.05M
EBIT -$497.94M
Net Income -$526.24M
Revenue Q/Q -14.56%
Revenue Y/Y N/A
P/E ratio -13.31
EV/Sales 1.02K
EV/EBITDA -15.73
EV/EBIT -15.35
P/S ratio 929.88
P/B ratio -18.13
Book/Share -3.94
Cash/Share 1.15
EPS -$5.37
ROA -65.08%
ROE 151.74%
Debt/Equity -3.13
Net debt/EBITDA -2.26
Current ratio 6.12
Quick ratio 6.12